RAINBOW1,450.00

Rainbow Childrens Medicare Ltd.

· Pharma & Health
₹ CrorePeersAPOLLOHOSPFORTISKIMSPOLYMEDPFIZERONESOURCEJUBLPHARMAVIJAYAMcap ₹14,726 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
RAINBOW
FY26
APOLLOHOSP
FY26
FORTIS
FY26
KIMS
FY26
Peer
Median
Valuation — at last close
P/E52.90×65.68×64.47×127.68×65.68× -19%
P/B8.85×12.79×6.61×12.04×12.04× -26%
EV/EBITDA26.26×34.86×33.39×42.36×34.86× -25%
Market Cap₹14,726 Cr₹1.28L Cr₹67,173 Cr₹30,796 Cr₹67,173 Cr -78%
Growth
Revenue CAGR 3Y13.22%14.94%13.17%21.12%14.94% -12%
Revenue CAGR 5Y19.03%17.76%24.04%19.03%
Net Income CAGR 3Y9.85%33.35%18.91%-12.87%18.91% -48%
Revenue YoY (latest Q)33.17%20.56%17.46%35.33%20.56% +61%
Net Income YoY (latest Q)16.23%38.41%2.26%-56.00%2.26% +618%
Profitability
EBITDA Margin31.95%14.94%22.84%20.54%20.54% +56%
Net Income Margin16.53%7.94%11.66%6.20%7.94% +108%
Return on Common Equity16.73%19.47%10.25%9.44%10.25% +63%
Return on Capital Employed15.19%18.41%11.81%7.96%11.81% +29%
Return on Assets10.15%9.02%6.67%3.12%6.67% +52%
Credit & Quality
Total Debt/Equity0.00×0.57×0.28×1.27×0.57× -100%
Interest Coverage5.07×6.44×5.20×2.56×5.20× -2%
Scale — latest FY
Revenue / Total Income₹1,703 Cr₹25,229 Cr₹9,128 Cr₹3,905 Cr₹9,128 Cr -81%
Net Income₹282 Cr₹2,003 Cr₹1,064 Cr₹242 Cr₹1,064 Cr -74%
Total Assets₹2,775 Cr₹22,197 Cr₹15,966 Cr₹7,759 Cr₹15,966 Cr -83%
EPS₹27.41₹135.04₹13.8₹6.03₹13.8 +99%
Book Value per Share₹163.81₹693.64₹134.69₹63.96₹134.69 +22%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.